OTC Head Lice Treatments Are Losing Effectiveness

This article originally appeared here.
Share this content:
OTC Head Lice Treatments Are Losing Effectiveness
OTC Head Lice Treatments Are Losing Effectiveness

FRIDAY, Sept. 9, 2016 (HealthDay News) -- Over-the-counter products have lost much of their effectiveness against head lice, according to research published in the September/October issue of Pediatric Dermatology.

Ellen Koch, M.D., a dermatologist with the University of Pittsburgh Medical Center, and colleagues examined hundreds of studies regarding head lice from 1985 to 2014. According to the findings, pyrethrins and permethrin have drastically lost effectiveness. Recent research in the United States has estimated their effectiveness level at 25 percent when combined with combing of nits. That level is no better than a placebo, according to the study.

The report also warns about the use of a prescription product called lindane, due to potential toxicity. And, the researchers said there's no evidence to support the home remedies of olive oil, mayonnaise, or petroleum jelly. There's also no evidence supporting the use of essential oils, such as tea tree oils, and there's also no safety data on these treatments, the study authors added. The report supports several prescription products: ivermectin (Sklice or Stromectol), malathion (Ovide), spinosad (Natroba) and benzyl alcohol (Ulesfia).

"The availability of proven and safe prescription remedies offers the opportunity to manage head louse infestations strategically and effectively," the authors write. "Given the current situation of resistance and apparent inefficacy of over-the-counter treatments, primary health care providers should understand how to manage head lice infestations, take an active role in the diagnosis of infections, and guide appropriate use of well-tested, proven, U.S. Food and Drug Administration-reviewed products."

Abstract
Full Text

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions

More in Home

FDA Approves New Parkinson's Add-On Drug Xadago

FDA Approves New Parkinson's Add-On Drug Xadago

To help prevent 'off' episodes among users of levodopa/carbidopa

Infant Mortality Down in United States From 2005 to 2014

Infant Mortality Down in United States From 2005 ...

Largest decreases seen for infants of Asian or Pacific Islander and non-Hispanic black women

Intensive Strategy Addresses Hypoxemia After Cardiac Surgery

Intensive Strategy Addresses Hypoxemia After Cardiac Surgery

Intensive alveolar recruitment strategy linked to less severe pulmonary complications after cardiac sx

is free, fast, and customized just for you!

Already a member?

Sign In Now »